Listed

Pharming Group N.V.

PHARNasdaqCIK 1828316HealthcareFiscal year ends Dec 31

Revenue is not reported in this company’s XBRL financial statements.

Latest quarter: not reported

Last eight quarters

Full statements
Pharming Group N.V., key figures for the last eight quarters
Line itemUnitShape over the periods
Revenue$
Gross margin%
Operating margin%
Net margin%
Diluted EPS$ per share
Free cash flow$

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$376.1mGross margin 87.9%
Diluted EPS$0.00, FY2025
Free cash flow$54.0m, FY2025
Pharming Group N.V., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m199Revenue, FY2021, twelve months to 2021-12-31$198.9m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2024-04-04, accession 0001828316-24-000008.Report this figure206Revenue, FY2022, twelve months to 2022-12-31$205.6m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2025-04-03, accession 0001828316-25-000017.Report this figure245Revenue, FY2023, twelve months to 2023-12-31$245.3m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2026-04-02, accession 0001828316-26-000015.Report this figure297Revenue, FY2024, twelve months to 2024-12-31$297.2m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2026-04-02, accession 0001828316-26-000015.Report this figure376Revenue, FY2025, twelve months to 2025-12-31$376.1m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2026-04-02, accession 0001828316-26-000015.Report this figure
Gross margin%89.4%Gross margin, FY2021, twelve months to 2021-12-31. gross profit / revenueGross profit: $177.7m. XBRL concept ifrs-full:GrossProfit. 20-F filed 2024-04-04, accession 0001828316-24-000008.Revenue: $198.9m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2024-04-04, accession 0001828316-24-000008.Report this figure91.5%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: $188.1m. XBRL concept ifrs-full:GrossProfit. 20-F filed 2025-04-03, accession 0001828316-25-000017.Revenue: $205.6m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2025-04-03, accession 0001828316-25-000017.Report this figure89.7%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: $220.1m. XBRL concept ifrs-full:GrossProfit. 20-F filed 2026-04-02, accession 0001828316-26-000015.Revenue: $245.3m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2026-04-02, accession 0001828316-26-000015.Report this figure88.1%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: $261.8m. XBRL concept ifrs-full:GrossProfit. 20-F filed 2026-04-02, accession 0001828316-26-000015.Revenue: $297.2m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2026-04-02, accession 0001828316-26-000015.Report this figure87.9%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: $330.6m. XBRL concept ifrs-full:GrossProfit. 20-F filed 2026-04-02, accession 0001828316-26-000015.Revenue: $376.1m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2026-04-02, accession 0001828316-26-000015.Report this figure
Operating margin%6.8%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $13.6m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2024-04-04, accession 0001828316-24-000008.Revenue: $198.9m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2024-04-04, accession 0001828316-24-000008.Report this figure8.9%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $18.2m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2025-04-03, accession 0001828316-25-000017.Revenue: $205.6m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2025-04-03, accession 0001828316-25-000017.Report this figure(2.2%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$5.4m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2026-04-02, accession 0001828316-26-000015.Revenue: $245.3m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2026-04-02, accession 0001828316-26-000015.Report this figure(2.9%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$8.6m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2026-04-02, accession 0001828316-26-000015.Revenue: $297.2m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2026-04-02, accession 0001828316-26-000015.Report this figure6.9%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $25.8m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2026-04-02, accession 0001828316-26-000015.Revenue: $376.1m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2026-04-02, accession 0001828316-26-000015.Report this figure
Net margin%8.0%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $16.0m. XBRL concept ifrs-full:ProfitLoss. 20-F filed 2024-04-04, accession 0001828316-24-000008.Revenue: $198.9m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2024-04-04, accession 0001828316-24-000008.Report this figure6.7%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $13.7m. XBRL concept ifrs-full:ProfitLoss. 20-F filed 2025-04-03, accession 0001828316-25-000017.Revenue: $205.6m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2025-04-03, accession 0001828316-25-000017.Report this figure(4.3%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$10.5m. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2026-04-02, accession 0001828316-26-000015.Revenue: $245.3m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2026-04-02, accession 0001828316-26-000015.Report this figure(4.0%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$11.8m. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2026-04-02, accession 0001828316-26-000015.Revenue: $297.2m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2026-04-02, accession 0001828316-26-000015.Report this figure0.8%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $2.9m. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2026-04-02, accession 0001828316-26-000015.Revenue: $376.1m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2026-04-02, accession 0001828316-26-000015.Report this figure
Diluted EPS$ per share0.02Diluted EPS, FY2021, twelve months to 2021-12-31$0.02 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2024-04-04, accession 0001828316-24-000008.Report this figure0.02Diluted EPS, FY2022, twelve months to 2022-12-31$0.02 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2025-04-03, accession 0001828316-25-000017.Report this figure(0.02)Diluted EPS, FY2023, twelve months to 2023-12-31−$0.02 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2026-04-02, accession 0001828316-26-000015.Report this figure(0.02)Diluted EPS, FY2024, twelve months to 2024-12-31−$0.02 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2026-04-02, accession 0001828316-26-000015.Report this figure0.00Diluted EPS, FY2025, twelve months to 2025-12-31$0.00 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2026-04-02, accession 0001828316-26-000015.Report this figure
Free cash flow$m27.1Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $37.8m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2024-04-04, accession 0001828316-24-000008.Capital expenditure: $10.7m. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2024-04-04, accession 0001828316-24-000008.Report this figure21.1Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $22.5m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2025-04-03, accession 0001828316-25-000017.Capital expenditure: $1.4m. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2025-04-03, accession 0001828316-25-000017.Report this figure(18.7)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$17.3m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2026-04-02, accession 0001828316-26-000015.Capital expenditure: $1.4m. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2026-04-02, accession 0001828316-26-000015.Report this figure(2.6)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$1.8m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2026-04-02, accession 0001828316-26-000015.Capital expenditure: $790.0k. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2026-04-02, accession 0001828316-26-000015.Report this figure54.0Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $54.7m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2026-04-02, accession 0001828316-26-000015.Capital expenditure: $749.0k. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2026-04-02, accession 0001828316-26-000015.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Pharming Group N.V.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
MAC Alpha Capital Management, LP2026-06-30$2.9m2,148,144New+2,148,144
Silverberg Bernstein Capital Management LLC2026-06-30$577.1k41,547Reduced−3,200
Crossmark Global Holdings, Inc.2026-06-30$169.0k12,463New+12,463
CITADEL ADVISORS LLC2026-06-30$162.3k11,972Added+1,783
MORGAN STANLEY2026-06-30$159.7k11,500Added+11
SmartHarvest Portfolios, LLC2026-06-30$144.7k10,415Reduced−382
Knoll Capital Management, LLC2026-06-30$56.8k4,091Added+34
Silver Grove Financial Group, Inc.2026-06-30$14.9k1,071New+1,071
Nalls Sherbakoff Group, LLC2026-06-30$12.1k870Not compared
Global Retirement Partners, LLC2026-06-30$6.3k456Not compared

Recent filings

All 146 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Pharming Group N.V., recent filings
FiledFormWhat it isAccession number
2026-10-2707:11 ET6-KReport of a foreign private issuerPeriod 2026-10-270001828316-26-000049
2026-10-2207:06 ET6-KReport of a foreign private issuerPeriod 2026-10-220001828316-26-000047
2026-10-1406:03 ET6-KReport of a foreign private issuerPeriod 2026-10-140001828316-26-000045
2026-09-2906:40 ET6-KReport of a foreign private issuerPeriod 2026-09-290001828316-26-000043
2026-09-2511:12 ET6-KReport of a foreign private issuerPeriod 2026-09-250001828316-26-000041
2026-09-2206:02 ET6-KReport of a foreign private issuerPeriod 2026-09-220001828316-26-000039
2026-09-1114:59 ET6-KReport of a foreign private issuerPeriod 2026-09-110001828316-26-000037
2026-08-1306:06 ET6-KReport of a foreign private issuerPeriod 2026-08-130001828316-26-000035
2026-07-3006:07 ET6-KReport of a foreign private issuerPeriod 2026-07-300001828316-26-000033
2026-06-0406:09 ET6-KReport of a foreign private issuerPeriod 2026-06-040001828316-26-000031

Latest annual report

Form 20-F for the fiscal year ended Dec 31, 2025Filed Apr 2, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
1828316
Tickers
PHAR
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
P7
Filer category
Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 07:12 ET. Listed shows no prices and gives no investment advice.